WO2018081083A1 - Nanoformulations d'ester de cholestéryle-phospholipide et procédés associés - Google Patents

Nanoformulations d'ester de cholestéryle-phospholipide et procédés associés Download PDF

Info

Publication number
WO2018081083A1
WO2018081083A1 PCT/US2017/058034 US2017058034W WO2018081083A1 WO 2018081083 A1 WO2018081083 A1 WO 2018081083A1 US 2017058034 W US2017058034 W US 2017058034W WO 2018081083 A1 WO2018081083 A1 WO 2018081083A1
Authority
WO
WIPO (PCT)
Prior art keywords
phospholipid
therapeutic agent
nanoparticle
paclitaxel
cholesteryl
Prior art date
Application number
PCT/US2017/058034
Other languages
English (en)
Inventor
Vuong Trieu
Original Assignee
Autotelic Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autotelic Llc filed Critical Autotelic Llc
Publication of WO2018081083A1 publication Critical patent/WO2018081083A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention relates to therapeutic agent nanoparticles, nanoparticle formulations suitable for injection, methods for administering therapeutic agents and for treating diseases and conditions treatable by the therapeutic agents using the formulations, in particular the formulation and characterization of nanoparticles containing taxanes such as paclitaxel.
  • the present invention further relates to methods of determining the usefulness of nanoparticles containing therapeutic agents based on cyclic voltammetry.
  • hydrophobic therapeutic agents are administered in delivery vehicles that are less than advantageous with regard to delivery properties including therapeutic agent dose and bioavailability. Furthermore, serious side effects are occasionally observed associated with the vehicle itself.
  • the formulation of paclitaxel over the years is an example of the challenges associated with many hydrophobic therapeutic agents.
  • Paclitaxel is one of the most effective chemotherapeutic drugs and is used to treat mainly breast, lung, and ovarian cancers.
  • Taxol ® is a paclitaxel formulation that utilizes a solvent, cremophor EL, to solubilize and deliver the essentially water-insoluble paclitaxel.
  • Paclitaxel has also been formulated as nanoparticles.
  • Abraxane ® is a nanoparticle paclitaxel formulation having improved paclitaxel solubility (0.35-0.7 ⁇ g/mL) compared to Taxol ® and avoids the use of a harmful solvent.
  • Abraxane ® is a human serum albumin-coated paclitaxel nanoparticle.
  • Cynviloq ® a polymeric micelle paclitaxel formulation that uses a biocompatible chemical polymer rather that a biological polymer to stabilize the nanoparticle, is a next-generation paclitaxel product.
  • the present invention provides therapeutic agent nanoparticles, nanoparticle formulations suitable for injection, methods for administering therapeutic agents and for treating diseases and conditions treatable by the therapeutic agents using the formulations.
  • the invention provides phospholipid-coated therapeutic agent nanoparticles.
  • the phospholipid-coated therapeutic agent nanoparticle comprises a particulate therapeutic agent coated with a cholesteryl ester and one or more phospholipids, wherein the nanoparticle is stable in aqueous delivery vehicles for administration and releases the therapeutic agent substantially instantaneously upon exposure to physiological fluid.
  • the nanoparticle is as stable in aqueous delivery vehicles for administration as synthetic polymeric micelles containing a therapeutic agent (Genexol- PM ® ) and is as effective in releasing the therapeutic agent under physiological conditions as a human- serum albumin-coated therapeutic agent (Abraxane ® ).
  • the phospholipid-coated therapeutic agent nanoparticle comprises a particulate therapeutic agent coated with a cholesteryl ester and one or more phospholipids, wherein the phospholipid is selected from the group consisting of a mono-acylphospholipid, a diacylphospholipid, and mixtures thereof.
  • the phospholipid-coated therapeutic agent nanoparticle consists essentially of a particulate therapeutic agent coated with a cholesteryl ester and one or more phospholipids.
  • the phospholipid-coated therapeutic agent nanoparticle consists of a particulate therapeutic agent coated with a cholesteryl ester and one or more phospholipids.
  • the cholesteryl ester has a fatty acid component having from 10 to 22 carbons. In other of these embodiments, the cholesteryl ester has a fatty acid component having from 12 to 20 carbons. In further of these embodiments, the cholesteryl ester has a fatty acid component having from 16 to 18 carbons.
  • the ratio of cholesteryl ester to phospholipid is from about 1:1000 to about 1:10 w/w. In other of these embodiments, the ratio of cholesteryl ester to phospholipid is from about 1:200 to about 1:50 w/w. In certain embodiments, the nanoparticle includes a therapeutic agent having an X log P greater than 2.0.
  • Suitable therapeutic agents include analgesics/antipyretics, anesthetics, antiasthmatics, antibiotics, antidepressants, antidiabetics, antifungal agents, antihypertensive agents, anti-inflammatories, antineoplastics, antianxiety agents, immunosuppressive agents, antimigraine agents, sedatives/hypnotics, antianginal agents, antipsychotic agents, antimanic agents, antiarrhythmics, antiarthritic agents, antigout agents, anticoagulants, thrombolytic agents, antifibrinolytic agents, hemorheologic agents, antiplatelet agents, anticonvulsants, antiparkinson agents, antihistamines/antipruritics, agents useful for calcium regulation, antibacterial agents, antiviral agents, antimicrobials, anti-infectives, bronchodilators, hormones, hypoglycemic agents, hypolipidemic agents, proteins, nucleic acids, agents useful for erythropoiesis stimulation, antiulcer
  • the therapeutic agent is a chemotherapeutic agent.
  • Representative chemotherapeutic agents include taxanes, such as paclitaxel and derivatives thereof, and docetaxel and derivatives thereof.
  • the therapeutic agent is paclitaxel.
  • the invention provides a pharmaceutical composition, comprising a nanoparticle of the invention.
  • the invention provides a unit dosage form for treating in an individual that includes a nanoparticle of the invention and a pharmaceutically acceptable carrier.
  • a kit is provided.
  • the kit comprises a container that includes a nanoparticle of the invention, and a container comprising a pharmaceutically acceptable carrier for reconstituting the nanoparticle.
  • the kit comprises a container that includes a nanoparticle of the invention suspended in a pharmaceutically acceptable carrier.
  • the kits optionally include instructions for using the kit in treating a disease or condition.
  • methods of treating a disease or condition in an individual are provided.
  • the methods comprise administering to an individual in need thereof an effective amount of the nanoparticle of the invention.
  • the disease or condition is a proliferative disease or condition.
  • the therapeutic agent is paclitaxel and the disease is a disease treatable by administering paclitaxel.
  • the therapeutic agent is paclitaxel and the disease is a cancer treatable by administering paclitaxel.
  • the nanoparticle is prepared by a microfluidization-solvent removal method. In another embodiment, the nanoparticle is prepared by a thin film-hydration method.
  • the invention provides synthetic high density lipoprotein (HDL) complexes of therapeutic agents, compositions that include complexes, methods for preparing the complexes and compositions, and methods for the use of the complexes and compositions. In one aspect, the invention provides a nanoparticle delivery vehicle comprising a high density lipoprotein complex.
  • HDL high density lipoprotein
  • the complex comprises: (a) a hydrophobic core having increased hydrophobicity compared to native high density lipoprotein, the core comprising (i) a lipid component, and (ii) a therapeutic agent, and, (b) a shell surrounding the core, the shell comprising a phospholipid.
  • the lipid component comprises apolipoprotein Al (ApoA-1).
  • the lipid component comprises cholesterol.
  • the lipid component comprises one or more cholesterol fatty acid esters. Representative cholesterol fatty acid esters include cholesteryl laurate, cholesteryl myristate, cholesteryl palmitate, cholesteryl stearate, cholesteryl oleate, and mixtures thereof.
  • the lipid component comprises one or more of a sphingomyelin, a cationic phospholipid, or a glycolipid.
  • the lipid component comprises a phosphatidylcholine.
  • Representative phosphatidylcholines include dimyristoylphosphatidylcholine (DMPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), egg yolk phosphatidylcholine (egg PC), soybean phosphatidylcholine, and mixtures thereof.
  • the lipid component comprises a mixture of a phosphatidylcholine, cholesterol, and a cholesterol fatty acid ester.
  • the therapeutic agent is a poorly water-soluble therapeutic agent.
  • Suitable therapeutic agents include chemotherapeutic agents.
  • the therapeutic agent is paclitaxel.
  • the phospholipid has increased hydrophobicity compared to phospholipids in native high density lipoprotein. Suitable phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, phosphatidic acids, and mixtures thereof.
  • diacylphosphatidylcholines include distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dilinoleoylphosphatidylcholine DLPC), palmitoyloleoylphosphatidylcholine (POPC), palmitoyllinoleoylphosphatidylcholine, stearoyllinoleoylphosphatidylcholine stearoyloleoylphosphatidylcholine, stearoylarachidoylphosphatidylcholine, didecanoylphosphatidylcholine (DDPC), dierucoylphosphatidylcholine (DEPC), dilinoleoylphosphatidylcholine (DLOPC), dimyristoylphosphatidylcholine (DMPC), myristoylpalmitoyl
  • the core is a substantially non-aqueous environment.
  • the invention provides a method for delivering a therapeutic agent to a subject.
  • the method comprises administering the nanoparticle delivery vehicle of the invention.
  • the vehicle is delivered parenterally, intravenously, intramuscularly, subcutaneously, transmucosally, or transdermally.
  • the invention provides a method for the treatment of cancer in a subject, comprising administering a therapeutically effective amount of the nanoparticle delivery vehicle of the invention to a subject in need thereof. In these methods, the cancer is treatable by the therapeutic agent.
  • the vehicle is delivered parenterally, intravenously, intramuscularly, subcutaneously, transmucosally, or transdermally.
  • Representative treatable cancers include prostate cancer, ovarian cancer, and breast cancer.
  • the invention provides a method for the treatment of an inflammatory disease in a subject, comprising administering a therapeutically effective amount of the nanoparticle delivery vehicle of the invention to a subject in need thereof. In these methods, the inflammatory disease is treatable by the therapeutic agent.
  • the invention provides a method for the treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of the nanoparticle delivery vehicle of the invention to a subject in need thereof. In these methods, atherosclerosis is treatable by the therapeutic agent.
  • the invention provides a method for making a nanoparticle delivery vehicle.
  • the method comprises: (a) mixing lipid components in a suitable organic solvent to give a lipid mixture; (b) adding a therapeutic agent to the lipid mixture to provide a lipid- therapeutic agent mixture; (c) drying the lipid-therapeutic agent mixture under nitrogen to provide a solid; (d) dispersing the solid in an aqueous solution to provide a dispersed mixture; (e) mixing the dispersed mixture in a buffer to provide a buffered mixture; (f) adding a suitable salt to the buffered mixture to provide a salt mixture; (g) adding a lipid binding protein to the salt mixture to provide a lipid binding protein mixture; (h) incubating the lipid binding protein mixture to provide an incubated mixture; and (i) subjecting the incubated mixture to dialysis with one or more buffer changes to facilitate the self-assembly and formation of a nanoparticle delivery vehicle.
  • the lipid components comprise a phosphatidylcholine, cholesterol, and a cholesterol ester.
  • the organic solvent is dimethyl sulfoxide.
  • the therapeutic agent is a poorly water-soluble therapeutic agent, such as a chemotherapeutic agent, for example, paclitaxel.
  • the invention provides a method for treating cancer in a subject by targeting cancer cells expressing a high density lipoprotein receptor.
  • the method comprises: administering to a subject in need thereof a therapeutically effective amount of a nanoparticle delivery vehicle of the invention, whereby the therapeutic agent is transferred to an endogenous plasma high density lipoprotein to provide a high density lipoprotein particle containing the therapeutic agent; wherein the high density lipoprotein particle containing the therapeutic agent associate with a cancer cell expressing a high density lipoprotein receptor, whereby the therapeutic agent is delivered to the cancer cell.
  • the high density lipoprotein receptor is a scavenger receptor type Bl (SR-B1).
  • administering the composition comprises systemic delivery, such as intravenous injection.
  • the therapeutic agent is a poorly water-soluble therapeutic agent, such as a chemotherapeutic agent, for example, paclitaxel.
  • the present invention also relates to method for monitoring formulated therapeutic agents using cyclic voltammetry by placing a volume of the formulated therapeutic agent on an electrode; placing the electrode in a potentiostat; and generating a cyclic voltammogram for the formulated therapeutic agent at a predetermined scan rate.
  • the present invention also relates to method for monitoring formulated therapeutic agents using cyclic voltammetry by placing a volume of the formulated therapeutic agent on an electrode; placing the electrode in a potentiostat; and generating a cyclic voltammogram for the formulated therapeutic agent where the scan rate is 0.005 to about 0.2 volts per second (V/s), the electrode is a screen printed carbon nanotube electrode, the therapeutic agent is formulated as a nanoparticle, therapeutic agent is formulated as a nanoparticle consisting of one or more phospholipids and one or more cholesteryl esters and the therapeutic agent is paclitaxel.
  • the present invention also relates to methods for devising optimized nanoparticles for drug delivery using cyclic voltammetry by placing a volume of the nanoparticle on an electrode; placing the electrode in a potentiostat; generating a cyclic voltammogram for the formulated therapeutic agent at a predetermined scan rate; and comparing the cyclic voltammogram to voltammograms of model systems. DESCRIPTION OF THE DRAWINGS
  • FIGURE 1 is a schematic illustration comparing the evolution of formulations for paclitaxel therapy.
  • FIGURE 2 shows the chemical structures of the lipids used in the preparation of representative paclitaxel nanoparticles of the invention.
  • FIGURE 3 compares particle size (nm) and paclitaxel entrapment efficiency (%) as a function of cholesteryl ester carbon chain length for representative paclitaxel nanoparticles of the invention.
  • FIGURE 4 illustrates particle size and size distribution (dynamic laser light scattering) for representative paclitaxel nanoparticles of the invention (PTX-NP formulation stabilized by combination of PC-10 and cholesteryl oleate.
  • FIGURE 5 compares particle size (nm) and paclitaxel entrapment efficiency (%) as a function of thin-film hydration water temperature for representative paclitaxel nanoparticles of the invention.
  • FIGURES 6A and 6B compare particle size (nm) and paclitaxel entrapment efficiency (%) as a function of amount of paclitaxel for representative paclitaxel nanoparticles of the invention prepared by thin-film hydration (Method 2) (phospholipid (PC-10) cholesteryl oleate) (LM-102) (6A), and phospholipid (PC-10)- lysophospholipid (lyso-PC-10) (LM-101) (6B).
  • Method 2 phospholipid (PC-10) cholesteryl oleate)
  • LM-101 phospholipid-10)- lysophospholipid
  • FIGURES 7A and 7B compare nanoparticle stabilities at refrigerated temperature (4°C) and room temperature (RT) for paclitaxel nanoparticles: representative paclitaxel nanoparticles of the invention (PC-10-cholesteryl oleate) (LM-102) (7A); and phospholipid (PC-lO)-lysophospholipid (lyso-PC-10) (LM- 101) (7B).
  • the formulations were prepared by thin-film hydration (Method 2) with paclitaxel amounts of 2.5 mg to 10 mg.
  • FIGURE 8 is a plot of the effect of storage time and temperature on paclitaxel nanoparticle size for one embodiment of nanoparticles of the present invention (LM-102).
  • FIGURE 9 is a plot the effect of sucrose on the freeze-thaw stability of one embodiment of nanoparticles of the present invention (LM-102).
  • FIGURE 10 is plot of the effective of additives (sucrose, PBS, histidine) on the lyophilization of paclitaxel- loaded nanoparticles of the present invention (LM-102).
  • FIGURE 11A is a cyclic voltammetry plot of a formulation of paclitaxel nanoparticles made by microfluidization-solvent evaporation at different scan rates
  • FIGURE 11B is a cyclic voltammetry plot of a formulation of paclitaxel nanoparticles made by thin film hydration at different scan rates.
  • FIGURE 12A is a cyclic voltammetry plot of a formulation of ghost red blood cell bilayer model system
  • FIGURE 12B is a cyclic voltammetry plot of a formulation of LDL monolayer model system
  • FIGURE 12C is a cyclic voltammetry plot of a formulation of HDL monolayer model system
  • FIGURE 12D is a cyclic voltammetry plot of a formulation of doxil encapsulated liposome system
  • FIGURE 12E is a cyclic voltammetry plot of a formulation of an Abraxane albumin-bound nanoparticle system.
  • FIGURE 13A is a plot of particle size and size distribution for 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI3, lOmg paclitaxel nanoparticle made by microfluidization-solvent evaporation
  • FIGURE 13B is a plot of particle size and size distribution for 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 , 2.5mg paclitaxel nanoparticle made by thin film evaporation
  • FIGURE 13C is a plot of particle size and size distribution for 50mg PC10, 0.5mg cholesteryl oleate, 15% EtOH in HCCI 3 , 2.5mg paclitaxel nanoparticle made by thin film evaporation
  • FIGURE 13D is a plot of particle size and size distribution for 40mg paclitaxel, 15% EtOH in HCCI3, 30mg/mL albumin nanoparticle made by microfluidization-solvent evaporation
  • FIGURE 14A is a cyclic voltammetry plot for 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 , lOmg paclitaxel nanoparticle made by microfluidization-solvent evaporation
  • FIGURE 14B is a cyclic voltammetry plot for 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 , 2.5mg paclitaxel nanoparticle made by thin film evaporation
  • FIGURE 14C is a cyclic voltammetry plot for 50mg PC10, 0.5mg cholesteryl oleate, 15% EtOH in HCCI 3 , 2.5mg paclitaxel nanoparticle made by thin film evaporation
  • FIGURE 14D is a cyclic voltammetry plot for 40mg paclitaxel, 15% EtOH in HCCI 3 , 30mg/mL albumin nanoparticle made by microfluid
  • FIGURE 15A is a cyclic voltammetry plot for 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 without drug nanoparticle made by microfluidization-solvent evaporation
  • FIGURE 15B is a cyclic voltammetry plot for 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 , without drug nanoparticle made by thin film evaporation
  • FIGURE 15C is a cyclic voltammetry plot for human serum albumin
  • FIGURE 15D is a cyclic voltammetry plot for Grifols stabilized human serum albumin
  • FIGURE 15E is a cyclic voltammetry plot for 40mg paclitaxel, 15% EtOH in HCCI 3 , Grifols stabilized human serum albumin.
  • the present invention provides paclitaxel nanoparticles, paclitaxel nanoparticle formulations suitable for injection, methods for administering paclitaxel and for treating diseases and conditions treatable by paclitaxel using the formulations.
  • Clinically successful paclitaxel nanoparticles formulations include Abraxane ® (an albumin bound nanoparticle paclitaxel) and Genexol-PM ® (a polymer bound nanoparticle paclitaxel).
  • Abraxane ® contains human-derived albumin and Genexol-PM ® utilizes a synthetic polymer to solubilize water insoluble paclitaxel.
  • the present invention utilizes biocompatible and injectable phospholipid and cholesteryl ester, components of lipoprotein nanoparticles, to provide a stable nanoparticle formulation of paclitaxel (PTX) for cancer treatment.
  • PTX paclitaxel
  • the effect of lipid composition and methods of preparation on drug loading and physical stability of the nanoparticle formulations are described.
  • the formulation parameters were evaluated for preparing the PTX nanoparticles included type of phospholipids and fatty acid chain lengths in cholesteryl ester, combination of phospholipid and cholesteryl esters. Process parameters, such as temperature of water for hydration, was studied and their impact on drug loading, particle size, and physical stability were evaluated.
  • the short-term stability evaluation of nanoparticles prepared with different cholesteryl esters demonstrated that 1-10% (w/w) of cholesteryl esters produced nanoparticle with a loading of about 42% paclitaxel with particle size of less than 275nm.
  • the formulations were found to be stable for 24h at 4°C.
  • the stability of the formulations was also evaluated at different temperatures before lyophilization with different amounts of drug loading.
  • the optimization of different parameters, such as drug amount and temperature of water for rehydration for stability of the formulations was performed and compared to the stability of phospholipid-lysophospholipid formulations of paclitaxel (LM-101).
  • the phospholipid-cholesteryl ester nanoparticle formulations of paclitaxel were successfully manufactured at laboratory scale.
  • PTX-NP phospholipid-cholesteryl ester paclitaxel nanoparticle
  • CMC Critical micelle concentration
  • Thin-film hydration method produced particles of greater paclitaxel loading than the microfluidization- solvent evaporation method.
  • PL or lyso-PL alone did not produce particles of having a size less than about 200 nm in either method. Both methods utilizing cholesteryl esters produced particles having a size less than 200 nm.
  • FIGURE 3 illustrates particle size and size distribution (dynamic laser light scattering) for representative paclitaxel nanoparticles of the invention (PTX-NP stabilized by combination of PC-10 and cholesteryl oleate (LM-102).
  • the cholesteryl oleate (CE) range from 0.1%, 1%, to 10% (wt/wt of total lipid weight). Optimal paclitaxel loading occurred at 1%-10% CE and 0.1% ineffective.
  • the formulation was filterable through 0.2 ⁇ filter and the filtered formulation has monomodal size distribution with a polydispersity index of 0.2.
  • the Zav of the optimized formulation was about 250 nm.
  • the drug loading efficiency and particle size of the formulations prepared with 20 PC-10 and cholesteryl oleate was evaluated at water rehydration temperatures from 40°C to 80°C. The data is shown in FIGURE 5. The greatest loading of paclitaxel was obtained at 40°C and the loading decreased as the temperature of the rehydration water increased. However, the particle size was observed to be about 250 nm for all the rehydration conditions.
  • the amount of paclitaxel used in the preparation of phospholipid (PC-10) cholesteryl oleate (LM-102) (2.5mg-10mg paclitaxel per 50 mg of lipid) and phospholipid (PC-lO)-lysophospholipid (lyso-PC-10) (80:20) affects paclitaxel loading 30 and nanoparticle size.
  • the effect of paclitaxel amount on particle size and entrapment efficiency for LM-102 and LM-101 prepared by Method 2 are compared in FIGURES 6A and 6B, respectively.
  • the particle size was smaller for LM-101 for paclitaxel in the range of 2.5 mg to 10 mg.
  • LM-102 There was a significant increase in the paclitaxel entrapment efficiency for LM-102 for lower paclitaxel amounts (2.5 mg to 5.0 mg).
  • the stabilities of LM-102 and LM-101 at refrigerated temperature (4°C) and room temperature (RT) are compared in FIGURES 7A and 7B, respectively.
  • the formulations were prepared by thin-film hydration (Method 2) with paclitaxel amounts of 2.5 mg to 10 mg.
  • LM-102 was found to be stable for 24h at 4°C for the paclitaxel loadings of 2.5 mg and 5 mg, whereas LM-101 was stable for 24h at 4°C for 2.5 mg drug loading.
  • the combination of PC-10 and cholesteryl oleate produced the smallest size PTX-NPs by Method 2.
  • the greatest entrapment efficiency (> 80%) was achieved for the LM-102 formulation.
  • water temperature of 40°C in the rehydration step produced the greatest paclitaxel loading.
  • LM-102 was stable for 24 h at 4 Q C.
  • LM-102 had a particle size of about 250 nm. Stability of LM-102 is greater than for LM-101 for formulations with 5 mg drug 20 loading.
  • PTX-phospholipid cholesteryl ester NPs were prepared by LV1 low volume Microfluidizer ® processor microfluidization.
  • the organic solvent containing PTX and phospholipids, and cholesteryl esters were added to an aqueous phase and the emulsion was run through the microfluidizer to obtain a nanoemulsion.
  • the solvent from the nanoemulsion was removed by rotary evaporation to obtain nanosuspension of PTX.
  • a thin film hydration method may be employed.
  • the phospholipid cholesteryl ester film was prepared by dissolving PTX and phospholipids and cholesteryl ester in ethanol. The dry film was hydrated with water for visual, microscopic, size and loading efficiency measurements of the resulting unfiltered and filtered formulation.
  • the particle size and the particle size distribution measurements may be determined using a Zetasizer Nano-ZS and the Zav hydrodynamic diameter of the samples was determined by cumulative analysis.
  • the particle size and particle size distribution by intensity were measured by photon correlation spectroscopy (PCS) using dynamic laser light scattering (4 mW He-Ne laser with a fixed wavelength of 633 nm, 173° backscatter at 25°C) in 10 mm diameter cells.
  • ELISA may be used to measure paclitaxel concentration in the PTX-NPs.
  • phospholipid-cholesteryl ester paclitaxel nanoparticles related formulations (e.g., LM- 102), and methods for their preparation are described above. It will be appreciated that other phospholipid-cholesteryl ester paclitaxel nanoparticles and related formulations of the invention can be prepared from the components described herein, including as described below. It will also be appreciated that therapeutic agents other than paclitaxel can be formulated as phospholipid-cholesteryl ester nanoparticles as described herein, and these nanoparticles and their formulations are also within the scope of the invention. In one aspect, the invention provides phospholipid-coated therapeutic agent nanoparticle.
  • the phospholipid-coated therapeutic agent nanoparticle comprises a particulate therapeutic agent coated with a cholesteryl ester and one or more phospholipids, wherein the nanoparticle is stable in aqueous delivery vehicles for administration (e.g., vehicles for injection) and releases the therapeutic agent substantially instantaneously upon exposure to or contact with a physiological fluid.
  • aqueous delivery vehicles for administration e.g., vehicles for injection
  • substantially instantaneously refers to release of the therapeutic agent from the nanoparticle within about 1 second, within about 2 seconds, within about 5 seconds, within about 10 seconds, or within about 30 seconds after contact with a physiological fluid, such as blood, serum, plasma (e.g., intravenous injection).
  • the phospholipid- coated therapeutic agent nanoparticle comprises a particulate therapeutic agent coated with a cholesteryl ester and one or more phospholipids, wherein the nanoparticle is as stable in aqueous delivery vehicles for administration as synthetic polymeric micelles containing a therapeutic agent (Genexol- 5 PM ® , Cynviloq ® ) and is as effective in releasing the therapeutic agent under physiological conditions as a human-serum albumin-coated therapeutic agent (Abraxane ® ).
  • a therapeutic agent Geneexol- 5 PM ® , Cynviloq ®
  • Abraxane ® a human-serum albumin-coated therapeutic agent
  • the phospholipid-coated therapeutic agent nanoparticle comprises a particulate therapeutic agent coated with a cholesteryl ester and one or more phospholipids, wherein the phospholipid is selected from a mono-acylphospholipid, a diacylphospholipid, or a mixture thereof.
  • the phospholipid-coated therapeutic agent nanoparticle consists essentially of a particulate therapeutic agent coated with a cholesteryl ester and one or more phospholipids.
  • the phospholipid-coated therapeutic agent nanoparticle consisting of a particulate therapeutic agent coated with a cholesteryl ester and one or more phospholipids.
  • the invention provides a phospholipid-coated therapeutic agent nanoparticle.
  • phospholipid-coated therapeutic agent nanoparticle refers to a nanoparticle comprising a therapeutic agent in particulate form coated with a cholesteryl ester and one or more phospholipids.
  • the phospholipid and cholesteryl ester coating the particulate therapeutic agent advantageously stabilizes the therapeutic agent and facilitates its effective administration.
  • the phospholipid-coated therapeutic agent nanoparticle advantageously provides for the effective formulation and delivery of hydrophobic or substantially water insoluble therapeutic agents.
  • Therapeutic agents advantageously formulated as nanoparticles of the invention include hydrophobic or substantially water-insoluble pharmacologically active agents (i.e., any bioactive agent having limited solubility in an aqueous or hydrophilic environment).
  • the solubility in water of these agents at 20-25°C may be 30 less than about 5, 2, 1, 0.5, 0.2, 0.1, 0.05, 0.02, or 0.01 mg/mL.
  • therapeutic agents such as chemotherapeutic agents, defined by their octanol/water partition coefficient X log P (Wang et al. Chem. Inf. Comput. Sci. 1997, 37, 615-621).
  • the coefficient for paclitaxel is 3.0.
  • therapeutic agents with X log P greater than 2.0 are excellent candidates for incorporation into the nanoparticles of the invention.
  • hydrophobic and substantially water-insoluble and “poorly water-soluble” refer to therapeutic agents having an octanol/water partition coefficient X log P greater than 2.0, and in certain embodiments greater than 3.0, and in other embodiments greater than 4.0.
  • Representative therapeutic agents include analgesics/antipyretics, anesthetics, antiasthmatics, antibiotics, antidepressants, antidiabetics, antifungal agents, antihypertensive agents, anti- inflammatories, antineoplastics, antianxiety agents, immunosuppressive agents, antimigraine agents, sedatives/hypnotics, antianginal agents, antipsychotic agents, antimanic agents, antiarrhythmics, antiarthritic agents, antigout agents, anticoagulants, thrombolytic agents, antifibrinolytic agents, hemorheologic agents, antiplatelet agents, anticonvulsants, antiparkinson agents, antihistamines/antipruritics, agents useful for calcium regulation, antibacterial agents, antiviral agents, antimicrobials, anti-infectives, bronchodilators, hormones, hypoglycemic agents, hypolipidemic agents, proteins, nucleic acids, agents useful for erythropoiesis stimulation, antiulcer/
  • the therapeutic agent is an antineoplastic selected from adriamycin, cyclophosphamide, actinomycin, bleomycin, daunorubicin, doxorubicin, epirubicin, mitomycin, methotrexate, fluorouracil, carboplatin, carmustine (BCNU), methyl- CCNU, cisplatin, etoposide, teniposide, daunomycin, indomethacin, biphenyl dimethyl dicarboxylate, interferon, camptothecin and derivatives thereof, phenesterine, paclitaxel and derivatives thereof, docetaxel and derivatives thereof, epothilones and derivatives thereof, vinblastine, vincristine, tamoxifen, etoposide, or piposulfan.
  • antineoplastic selected from adriamycin, cyclophosphamide, actinomycin, bleomycin, daunorubicin,
  • antineoplastic agents include taxanes and their derivatives, such as paclitaxel.
  • the therapeutic agent is an immunosuppressive agent selected from cyclosporine, azathioprine, mizoribine, or FK506 (tacrolimus).
  • the therapeutic agent nanoparticle of the invention includes one or more phospholipids coating the therapeutic agent.
  • phospholipid refers to a class of lipids having a hydrophobic tail (e.g., one or two) and a phosphate head group.
  • Hydrophilicity is conferred to the phospholipid by it phosphate head group and hydrophobicity is conferred to the phospholipid by apolar groups that include long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic groups (e.g., fatty acid acyl groups).
  • apolar groups that include long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic groups (e.g., fatty acid acyl groups).
  • phospholipid refers to phosphatidic acids, phosphoglycerides, and phosphosphingolipids. Phosphatidic acids include a phosphate group coupled to a glycerol group, which may be mono- or diacylated.
  • Phosphoglycerides include a phosphate group intermediate an organic group (e.g., choline, ethanolamine, serine, inositol) and a glycerol group, which may be mono- or diacylated.
  • Phosphosphingolipids include a phosphate group intermediate an organic group (e.g., choline, ethanolamine) and a sphingosine (non-acylated) or ceramide (acylated) group.
  • the phospholipids useful in the compositions and methods of the invention include their salts (e.g., sodium, ammonium).
  • phospholipids that include carbon- carbon double bonds, individual geometrical isomers (cis, trans) and mixtures of isomers are included.
  • Representative phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, and phosphatidic acids, and their lysophosphatidyl (e.g., lysophosphatidylcholines and lysophosphatidylethanolamine) and diacyl phospholipid (e.g., diacylphosphatidylcholines, diacylphosphatidylethanolamines, diacylphosphatidylglycerols, diacylphosphatidylserines, diacylphosphatidylinositols, and diacylphosphatidic acids) counterparts.
  • lysophosphatidyl e.g., lyso
  • the acyl groups of the phospholipids may be the same or different.
  • the acyl groups are derived from fatty acids having C10-C24 carbon chains (e.g., acyl groups such as decanoyl (CIO), dodecanoyl (also known as lauroyl) (C12), ATLC ⁇ 57042AP -18- tetradecanoyl (also known as myristoyl) (C14), hexadecanoyl (also known as palmitoyl) (C16), octadecanoyl (also known as stearoyl) (C18), oleoyl, linoleoyl, linolenoyl, arachidonoyl groups).
  • CIO decanoyl
  • dodecanoyl also known as lauroyl
  • ATLC ⁇ 57042AP -18- tetradecanoyl also known as myristoyl
  • C16 hexadecanoyl
  • diacylphosphatidylcholines include distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dilinoleoylphosphatidylcholine (DLPC), palmitoyloleoylphosphatidylcholine (POPC), palmitoyllinoleoylphosphatidylcholine, stearoyllinoleoylphosphatidylcholine stearoyloleoylphosphatidylcholine, stearoylarachidoylphosphatidylcholine, didecanoylphosphatidylcholine (DDPC), didodecanoylphosphatidylcholine, dierucoylphosphatidylcholine (DEPC), d
  • diacylphosphatidylethanolamines include dioleoylphosphatidylethanolamine (DOPE), dipalmitoylphosphatidylethanolamine (DPPE), distearoylphosphatidylethanolamine (DSPE), dilauroylphosphatidylethanolamine (DLPE), dimyristoylphosphatidylethanolamine (DM PE), dierucoylphosphatidylethanolamine (DEPE), didecanoylphosphatidylethanolamine, didodecanoylphosphatidylethanolamine, and palmitoyloleoylphosphatidylethanolamine (POPE).
  • DOPE dioleoylphosphatidylethanolamine
  • DPPE dipalmitoylphosphatidylethanolamine
  • DSPE distearoylphosphatidylethanolamine
  • DLPE dimyristoylphosphatidylethanolamine
  • DEPE dierucoylphosphatidylethanolamine
  • diacylphosphatidylglycerols include dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dierucoylphosphatidylglycerol (DEPG), dilauroylphosphatidylglycerol (DLPG), dimyristoylphosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), didecanoylphosphatidylglycerol, didodecanoylphosphatidylglycerol, and palmitoyloleoylphosphatidylglycerol (POPG).
  • DOPG dioleoylphosphatidylglycerol
  • DPPG dipalmitoylphosphatidylglycerol
  • DEPG dierucoylphosphatidylglycerol
  • DLPG dimyristoylphosphatidyl
  • diacylphosphatidylserines include dilauroylphosphatidylserine (also known as ATLC ⁇ 57042AP -19- didodecanoylphosphatidylserine) (DLPS), dioleoylphosphatidylserine (DOPS), dipalmitoylphosphatidylserine (DPPS), didecanoylphosphatidylserine, and distearoylphosphatidylserine (DSPS).
  • DLPS dilauroylphosphatidylserine
  • DOPS dioleoylphosphatidylserine
  • DPPS dipalmitoylphosphatidylserine
  • DSPS distearoylphosphatidylserine
  • diacylphosphatidic acids include dierucoylphosphatidic acid (DEPA), dilauroylphosphatidic acid (also known as didodecanoylphosphatidic acid) (DLPA), dimyristoylphosphatidic acid (DMPA), dioleoylphosphatidic acid (DOPA), dipalmitoylphosphatidic acid (DPPA), didecanoylphosphatidic acid, and distearoylphosphatidic acid (DSPA).
  • DEPA dierucoylphosphatidic acid
  • DLPA dilauroylphosphatidic acid
  • DMPA dimyristoylphosphatidic acid
  • DOPA dioleoylphosphatidic acid
  • DPPA dipalmitoylphosphatidic acid
  • DSPA distearoylphosphatidic acid
  • Representative phospholipids include phosphosphingolipids such as ceramide phosphoryllipid, ceramide phosphorylcholine, and ceramide phosphorylethanolamine.
  • the nanoparticles of the invention include two or more different phospholipids. In certain embodiments, the nanoparticle includes two different phospholipids. In other embodiments, the nanoparticle includes three different phospholipids. In further embodiments, the nanoparticle includes four different phospholipids. In certain embodiments, the nanoparticle of the invention further includes a sterol (e.g., cholesterol). As noted above, in certain embodiments, the phospholipid is a diacylphospholipid.
  • diacylphospholipids include diacylphosphatidylcholines, diacylphosphatidylethanolamines, diacylphosphatidylglycerols, diacylphosphatidylserines, diacylphosphatidylinositols, and diacylphosphatidic acids.
  • the diacylphospholipid e.g., phosphatidylcholine
  • the diacylphospholipid has a fatty acid component (acyl groups) having from 10 to 22 carbons (e.g., 10, 12, 14, 16, 18, 20, 22 carbons).
  • the diacylphospholipid has a fatty acid component having from 10 to 20 carbons (e.g., 10, 12, 14, 16, 18, 20 carbons).
  • the diacylphospholipid has a fatty acid component having from 10 to 16 carbons (e.g., 10, 12, 14, 16 carbons). In further embodiments, the diacylphospholipid has a fatty acid component having from 10 to 14 carbons (e.g., 10, 12, 14 carbons). In yet other embodiments, the diacylphospholipid has a fatty acid component having from 10 to 12 carbons (e.g., 10, 12 carbons). In certain embodiments, the diacylphospholipid has a fatty acid component having 10 carbons.
  • each of the fatty acid components in the diacylphospholipid has the same number of carbons (e.g., 10, 12, 14, 16, 18, 20, 22 carbons), such as 1,2-didecanoylphosphatidylcholine, and that in other of the embodiments noted above, each of the fatty acid components in the diacylphospholipid has a different number of carbons, such as stearoyloleoylphosphatidylcholine.
  • the phospholipid is a phosphatidylcholine.
  • Suitable phosphatidylcholines include phosphatidylcholines having a fatty acid component (acyl groups) having from 10 to 22 carbons (e.g., 10, 12, 14, 16, 18, 20, 22 carbons).
  • the phosphatidylcholine has a fatty acid component having from 10 to 20 carbons (e.g., 10, 14, 16, 18, 20 carbons).
  • the phosphatidylcholine has a fatty acid component having from 10 to 16 carbons (e.g., 10, 12, 14, 16 carbons).
  • the phosphatidylcholine has a fatty acid component having from 10 to 14 carbons (e.g., 10, 12, 14 carbons).
  • the phosphatidylcholine has a fatty acid component having from 10 to 12 carbons (e.g., 10, 12 carbons). In certain embodiments, the phosphatidylcholine has a fatty acid component having 10 carbons. It will be appreciated that the fatty acid component of a particular phospholipid need not be the same (i.e., diacyl with different acyl groups). In certain embodiments, the phospholipid is an electronically neutral phospholipid having, for example, a negatively charged phosphate group and a positively charged amine group (e.g., a phosphatidylcholine or phosphatidylethanolamine).
  • the phospholipid is an electronically negative phospholipid having a negatively charged phosphate group (e.g., a phosphatidylglycerol).
  • the phospholipid is a lysophospholipid.
  • the lysophospholipid is a mono-acylphospholipid.
  • lysophospholipids include lysophosphatidylcholines, lysophosphatidylethanolamines, lysophosphatidylglycerols, lysophosphatidylserines, lysophosphatidylinositols, and lysophosphatidic acids (e.g., mono-acylphosphatidyl compounds).
  • the mono-acylphospholipid e.g., lysophosphatidylcholine
  • the monoacylphospholipid has a fatty acid component having from 10 to 20 carbons (e.g., 10, 12, 14, 16, 18, 20 carbons). In other embodiments, the mono-acylphospholipid has a fatty acid component having from 10 to 16 carbons (e.g., 10, 12, 14, 16 carbons). In further embodiments, the mono-acylphospholipid has a fatty acid component having from 10 to 14 carbons (e.g., 10, 12, 14 carbons). In yet other embodiments, the mono-acylphospholipid has a fatty acid component having from 10 to 12 carbons (e.g., 10, 12 carbons). In certain embodiments, the mono-acylphospholipid has a fatty acid component having 10 carbons.
  • the phospholipid is a lysophosphatidylcholine.
  • Suitable lysophosphatidylcholines include lysophosphatidylcholines having a fatty acid component (acyl group) having from 10 to 22 carbons (e.g., 10, 12, 14, 16, 18, 20, 22 carbons).
  • the phosphatidylcholine has a fatty acid component having from 10 to 20 carbons (e.g., 10, 14, 16, 18, 20 carbons).
  • the lysophosphatidylcholine has a fatty acid component having from 10 to 16 carbons (e.g., 10, 12, 14, 16 carbons).
  • the lysophosphatidylcholine has a fatty acid component having from 10 to 14 carbons (e.g., 10, 12, 14 carbons). In yet other embodiments, the lysophosphatidylcholine has a fatty acid component having from 10 to 12 carbons (e.g., 10, 12 carbons). In certain embodiments, the lysophosphatidylcholine has a fatty acid component having 10 carbons. In certain embodiments, the lysophospholipid is an electronically neutral lysophospholipid having, for example, a negatively charged phosphate group and a positively charged amine group (e.g., a lysophosphatidylcholine or lysophosphatidylethanolamine).
  • the lysophospholipid is an electronically negative lysophospholipid having a negatively charged phosphate group (e.g., a lysophosphatidylglycerol).
  • the nanoparticle of the invention includes a diacylphospholipid and a mono-acylphospholipid.
  • the nanoparticle of the invention includes a phosphatidylcholine and a lysophosphatidylcholine. The ratio of di- to mono- acylphospholipid (e.g., phosphatidylcholine to lysophosphatidylcholine) is from about 1:99 w/w percent to about 99:1 w/w percent.
  • the ratio of di- to mono-acylphospholipid is about 10:90 to about 90:10 w/w percent. In other embodiments, the ratio of di- to mono-acylphospholipid (e.g., phosphatidylcholine to lysophosphatidylcholine) is about 20:80 to about 80:20 w/w percent. In further embodiments, the ratio of di- to mono-acylphospholipid (e.g., phosphatidylcholine to lysophosphatidylcholine) is about 30:70 to about 70:30 w/w percent.
  • the ratio of di- to mono-acylphospholipid is about 40:60 to about 60:40 w/w percent. In certain embodiments, the ratio of di- to mono-acylphospholipid (e.g., phosphatidylcholine to lysophosphatidylcholine) is about 50:50 w/w percent. In certain embodiments, the ratio of di- to mono- acylphospholipid (e.g., phosphatidylcholine to lysophosphatidylcholine) is from about 90:10 to about 60:40 w/w percent.
  • the ratio of di- to mono-acylphospholipid is from about 90:10 to about 70:30 w/w percent. In further embodiments, the ratio of di- to mono-acylphospholipid (e.g., phosphatidylcholine to lysophosphatidylcholine) is about 80:20 w/w percent.
  • the nanoparticle includes a diacylphospholipid (e.g., a phosphatidylcholine) and a mono- acylphospholipid (e.g., lysophosphatidylcholine), the fatty acid components of the di- and mono- acylphospholipids are the same.
  • a diacylphospholipid e.g., a phosphatidylcholine
  • a mono- acylphospholipid e.g., lysophosphatidylcholine
  • each of the di- and mono-acylphospholipids includes CIO (decanoyl) fatty acid components, each includes C12 (dodecanoyl) fatty acid components, each includes C14 (tetradecanoyl) fatty acid components, each includes C16 (hexadecanoyl) fatty acid components, or each includes C18 (dodecanoyl) fatty acid components.
  • the fatty acid components of the di- and mono-acylphospholipids are different (e.g., the diacylphospholipid includes CIO fatty acid components and the mono-acylphospholipid includes a C12 fatty acid component.
  • the therapeutic agent nanoparticle of the invention includes one or more cholesteryl esters.
  • cholesteryl ester refers to an ester of cholesterol that may be produced from esterification of cholesterol with a carboxylic acid. The ester bond is formed between the carboxylate group of the carboxylic acid (e.g., fatty acid) and the hydroxyl group of cholesterol.
  • the cholesteryl ester is a cholesteryl fatty acid ester (i.e., the carboxylic acid in the production process is a fatty acid).
  • Cholesteryl esters can be characterized by the nature of carboxylic acid component.
  • Representative cholesteryl esters include shortchain carboxylic acid components having less than six carbons, medium-chain carboxylic acid components having from six to twelve carbons, long-chain carboxylic acid components having from thirteen to twenty-one carbons, and very long-chain carboxylic acid components having greater than twenty-two carbons.
  • the carboxylic acid components may have carbon chains that are straight chains or branched chains.
  • the carboxylic acid components may have carbon chains that saturated or unsaturated (having one or more carbon-carbon double bonds). The configuration of each double bond may be cis or trans.
  • the carboxylic acid component of the cholesteryl ester has from 4 to 18 carbons. In other embodiments, the carboxylic acid component of the cholesteryl ester has from 8 to 16 carbons.
  • the carboxylic acid component of the cholesteryl ester has from 8 to 12 carbons. In one embodiment, the carboxylic acid component of the cholesteryl ester has 10 carbons. In another embodiment, the carboxylic acid component of the cholesteryl ester has 12 carbons. In a further embodiment, the carboxylic acid component of the cholesteryl ester has 18 carbons. In certain embodiments, the cholesteryl ester is present in the nanoparticle in an amount from about 0.1 to about 10% by weight of the total amount of phospholipid(s). In other embodiments, the cholesteryl ester is present in the nanoparticle in an amount from about 1 to about 10% by weight of the total amount of phospholipid(s).
  • the cholesteryl ester is present in the nanoparticle in an amount from about 5 to about 10% by weight of the total amount of phospholipid(s).
  • the cholesteryl ester, phospholipid, and therapeutic agent in the composition can be associated in various manners.
  • the cholesteryl ester and phospholipid is an admixture with the therapeutic agent.
  • the cholesteryl ester and phospholipid encapsulate or entrap the therapeutic agent.
  • the cholesteryl ester and phospholipid are bound (e.g., noncovalently bound) to the therapeutic agent.
  • the nanoparticles of the invention have an average or mean diameter of no greater than about any of about 1000, 900, 800, 700, 600, 500, 400, 300, 200, or 100 nm. In some embodiments, the average or mean diameter of the particles is between about 30-300 nm. In some embodiments, the average or mean diameter of the particles is between about 20-200 nm. In some embodiments, the average or mean diameter of the particles is between about 80-200 nm. In certain embodiments, the average or mean diameter of the particles is between about 30-180 nm. In some embodiments, the average or mean diameter of the particles is between about 40-160 nm. In certain embodiments, the average or mean diameter of the particles is between about 80-140 nm. In other embodiments, the average or mean diameter of the particles is between about 90-120 nm. In some embodiments, the particles are sterile-filterable.
  • the nanoparticle can be electronically neutral or charged.
  • the nanoparticle when the nanoparticle includes only phospholipids (e.g., di- and/or mono-acylphospholipids) that are electronically neutral (e.g., a phosphatidylcholine, lysophosphatidylcholine, phosphatidylethanolamine, and/or lyso phosphatidylethanolamine, each having a negatively charged phosphate group and a positively charged amine group), the nanoparticle is electronically neutral, at least in regard to the nanoparticle's phospholipid component.
  • phospholipids e.g., di- and/or mono-acylphospholipids
  • the nanoparticle is electronically neutral, at least in regard to the nanoparticle's phospholipid component.
  • the nanoparticle when the nanoparticle includes a phospholipid (e.g., di- and/or mono-acylphospholipid) that is negatively charged (e.g., a phosphatidylglycerol having a negatively charged phosphate group and no corresponding positively charged group), the nanoparticle is electronically negative, at least in regard to the nanoparticle's phospholipid component.
  • the nanoparticle is electronically neutral in regard to the nanoparticle's phospholipid content.
  • the nanoparticle is electronically negative (negatively charged) in regard to the nanoparticle's phospholipid content.
  • Representative nanoparticles of the invention demonstrate pharmacokinetic bioequivalence to Abraxane ® with large volume of distribution, low AUC, and low Cmax in comparison to solvent-based paclitaxel formulations, such as Taxol ® or Tocosol ® .
  • Cynviloq ® provides the desired pharmacokinetic bioequivalence to Abraxane ® , but suffers from undesirable hypersensitivity to its excipient/polymer. This prompted the replacement of mPEG-PDLLA in Cynviloq ® with naturally- occurring phospholipids.
  • the nanoparticles of the invention comprise the components described herein.
  • the nanoparticles of the invention consist essentially of the components described herein, and that in these embodiments the nanoparticles do not include any additional component that would material affect the properties of the nanoparticle (e.g., therapeutic function, effect, or other pharmacokinetic properties).
  • the nanoparticles of the invention consist of the components described herein, and that in these embodiments the nanoparticles do not include any additional components.
  • Phospholipid-Coated Therapeutic Agent Nanoparticle Compositions are provided. Representative compositions include dry and liquid compositions.
  • the composition comprises a dry (e.g., lyophilized) composition.
  • the composition is a liquid (e.g., aqueous) composition obtained by reconstituting or resuspending a dry composition.
  • the composition is an intermediate liquid (e.g., aqueous) composition that can be dried (e.g., lyophilized). Dry compositions of the invention can be reconstituted, resuspended, or rehydrated to form generally a stable aqueous suspension of particles comprising the therapeutic agent and phospholipid (e.g., phospholipid-coated therapeutic agent).
  • a hydrophobic therapeutic agent is "stabilized" by a phospholipid in an aqueous suspension if it remains suspended in an aqueous medium (e.g., without visible precipitation or sedimentation) for an extended period of time, such as for at least about any of 0.1, 0.2, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 36, 48, 60, or 72 hours.
  • the suspension is generally, but not necessarily, suitable for administration to a subject (e.g., human).
  • the stability of the suspension is in some embodiments evaluated at room temperature (e.g., 20-25 °C) or refrigerated conditions (e.g., 4 °C).
  • the composition is a liquid (e.g., aqueous) composition obtained by reconstituting or resuspending a dry composition in a biocompatible medium.
  • Suitable biocompatible media include, but are not limited to, water, buffered aqueous media, saline, buffered saline, optionally buffered solutions of amino acids, optionally buffered solutions of proteins, optionally buffered solutions of sugars, optionally buffered solutions of vitamins, optionally buffered solutions of synthetic polymers, lipid-containing emulsions, and the like.
  • the amount of phospholipid in the composition described herein will vary depending on the therapeutic agent and other components in the composition.
  • the composition comprises a phospholipid in an amount that is sufficient to stabilize the therapeutic carrier in an aqueous suspension, for example, in the form of a stable colloidal suspension (e.g., a stable suspension of nanoparticles).
  • the phospholipid is in an amount that reduces the sedimentation rate of the therapeutic agent in an aqueous medium.
  • the amount of the phospholipid also depends on the size and density of particles of the therapeutic agent.
  • the phospholipid is present in an amount that is sufficient to stabilize the therapeutic agent in an aqueous suspension at a certain concentration.
  • the concentration of the therapeutic agent in the composition is about 0.1 to about 100 mg/ml, including, for example, any of about 0.1 to about 50 mg/ml, about 0.1 to about 20 mg/ml, about 1 to about 10 mg/ml, about 2 to about 8 mg/ml, and about 4 to about 6 mg/ml.
  • the concentration of the therapeutic agent is at least about any of about 1.3 mg/ml, 1.5 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 20 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 15 mg/ml, 20 mg/ml, 25 mg/ml, 30 mg/ml, 40 mg/ml, and 50 mg/ml.
  • the phospholipid is present in an amount that avoids use of surfactants (such as Tween 80 or Cremophor or other biocompatible polymers).
  • the compositions of the invention are advantageously free or substantially free of surfactants (such as Tween 80 and Cremophor) and other biocompatible polymers (e.g., serum albumins, such as human serum albumin, and synthetic polymers such as poly (alkylene oxide)-containing polymers as described in U.S. Patent No. 6,322,805).
  • the composition, in liquid form comprises from about 0.1% to about 50% (w/v) (e.g., about 0.5% (w/v), about 5% (w/v), about 10% (w/v), 30 about 15% (w/v), about 20% (w/v), about 30% (w/v), about 40% (w/v), about 50% (w/v)) of the phospholipid.
  • the composition in liquid form, comprises about 0.5% to about 5% (w/v) of the phospholipid.
  • the weight ratio of phospholipid to the therapeutic agent is such that a sufficient amount of the therapeutic agent binds to, or is transported by, the cell.
  • the weight ratio of phospholipid to therapeutic agent can be optimized for different phospholipid and therapeutic agent combinations, generally the weight ratio of phospholipid to therapeutic agent (w/w) is about 0.01:1 to about 100:1, including for example any of about 0.02:1 to about 50:1, about 0.05:1 to about 20:1, about 0.1:1 to about 20:1, about 1:1 to about 18:1, about 2:1 to about 15:1, about 3:1 to about 12:1, about 4:1 to about 10:1, about 5:1 to about 9:1, and about 9:1.
  • the phospholipid to therapeutic agent weight ratio is about any of 18:1 or less, such as about any of 15:1 or less, 14:1 or less, 13:1 or less, 12:1 or less, 11:1 or less, 10:1 or less, 9:1 or less, 8:1 or less, 7:1 or less, 6:1 or less, 5:1 or less, 4:1 or less, and 3:1 or less.
  • the phospholipid allows the composition to be administered to a subject (e.g., human) without significant side effects.
  • the phospholipid is in an amount that is effective to reduce one or more side effects of administration of the therapeutic agent to a human.
  • reducing one or more side effects of administration of the therapeutic agent refers to reduction, alleviation, elimination, or avoidance of one or more undesirable effects caused by the therapeutic agent, as well as side effects caused by delivery vehicles (such as solvents that render the therapeutic suitable for injection) used to deliver the therapeutic agent.
  • side effects include, for example, myelosuppression, neurotoxicity, hypersensitivity, inflammation, venous irritation, phlebitis, pain, skin irritation, peripheral neuropathy, neutropenic fever, anaphylactic reaction, venous thrombosis, extravasation, and combinations thereof.
  • compositions described herein can include other agents, excipients, or stabilizers to improve properties of the composition.
  • suitable excipients and diluents include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, 30 tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, saline solution, syrup, methylcellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate and mineral oil.
  • the formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents.
  • emulsifying agents include tocopherol esters such as tocopheryl polyethylene glycol succinate and the like, Pluronic, emulsifiers based on polyoxyethylene compounds, Span 80 and related compounds, and other emulsifiers known in the art and approved for use in animals or human dosage forms.
  • the compositions can be formulated so as to provide rapid, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • compositions for administration by injection include those comprising a therapeutic agent as the active ingredient in association with a surface-active agent (or wetting agent or surfactant), or in the form of an emulsion (e.g., as a water-in-oil or oil-in-water emulsion).
  • a surface-active agent or wetting agent or surfactant
  • Other ingredients can be added, for example, mannitol or other pharmaceutically acceptable vehicles, if necessary.
  • the composition is suitable for administration to a human.
  • the composition is suitable for administration to a mammal, such as, in the veterinary context, including domestic pets and agricultural animals.
  • the following formulations and methods are merely exemplary and are in no way limiting.
  • Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice, (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules, (c) suspensions in an appropriate liquid, (d) suitable emulsions, and (e) powders.
  • Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients.
  • Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
  • a flavor usually sucrose and acacia or tragacanth
  • pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation compatible with the blood of the intended recipient, and aqueous and nonaqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
  • the composition is formulated to have a pH in the range of about 4.5 to about 9.0, including for example pH in the ranges of any of about 5.0 to about 8.0, about 6.5 to about 7.5, and about 6.5 to about 7.0.
  • the pH of the composition is formulated to no less than about 6, including for example no less than about any of 6.5, 7, or 8 (such as about 7.5 or about 8).
  • the composition can also be made to be isotonic with blood by the addition of a suitable tonicity modifier, such as glycerol.
  • compositions of the invention comprise the components described herein (e.g., may include other component such as described below).
  • the compositions of the invention consist essentially of the components described herein, and that in these embodiments the compositions do not include any additional component that would material affect the properties of the nanoparticle (e.g., therapeutic function, effect, or other pharmacokinetic properties).
  • the compositions of the invention consist of the components described herein, and that in these embodiments the compositions do not include any additional components.
  • the invention provides articles of manufacture comprising the compositions described herein in suitable packaging.
  • suitable packaging for compositions described herein are known in the art, and include, for example, vials (such as sealed vials), vessels (such as sealed vessels), ampules, bottles, jars, flexible packaging (such as sealed Mylar or plastic bags), and the like. These articles of manufacture may further be sterilized and/or sealed.
  • unit dosage forms comprising the compositions described herein. These unit dosage forms can be stored in a suitable packaging in single or multiple unit dosages and may also be further sterilized and sealed.
  • kits comprising compositions (or unit dosages forms and/or articles of manufacture) described herein and may further comprise instruction(s) on methods of using the composition, such as uses further described herein.
  • the kit of the invention comprises the packaging described above.
  • the kit of the invention comprises the packaging described above and a second packaging comprising a buffer. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein.
  • Kits may also be provided that contain sufficient dosages of the therapeutic agent as disclosed herein to provide effective treatment for an individual for an extended period, such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months or more. Kits may also include multiple unit doses of the therapeutic agent and pharmaceutical compositions and instructions for use and packaged in quantities sufficient for storage and use in pharmacies, for example, hospital pharmacies and compounding pharmacies.
  • the invention provides methods for using the phospholipid coated therapeutic agent nanoparticles.
  • the invention provides a method for treating a disease or condition that is responsive to a therapeutic agent comprising administering a composition comprising an effective amount of the phospholipid-coated therapeutic agent nanoparticle.
  • a method of treating cancer in an individual comprising administering to the individual a composition comprising an effective amount of a antineoplastic therapeutic agent (such as paclitaxel) and a phospholipid protein.
  • an effective amount refers to an amount of a compound or composition sufficient to treat a specified disorder, condition or disease such as ameliorate, palliate, lessen, and/or delay one or more of its symptoms.
  • an effective amount comprises an amount sufficient to cause a tumor to shrink and/or to decrease the growth rate of the tumor (such as to suppress tumor growth).
  • an effective amount is an amount sufficient to delay development.
  • an effective amount is an amount sufficient to prevent occurrence and/or recurrence.
  • An effective amount can be administered in one or more administrations.
  • compositions of the invention are effective for treating proliferative diseases including cancers, restenosis, and fibrosis, among others.
  • the therapeutic agent is paclitaxel
  • the compositions are effective for treating diseases and conditions treatable by administering paclitaxel.
  • Cancers to be treated by compositions described herein include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
  • cancers that can be treated by compositions described herein include, but are not limited to, squamous cell cancer, lung cancer (including small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung), cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, melanoma, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, head and neck cancer, colorectal cancer, rectal cancer, soft-tissue sarcoma, Kaposi's sarcoma, B-cell lymphoma (including low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL)
  • metastatic cancer that is, cancer that has metastasized from the primary tumor.
  • a method of reducing cell proliferation and/or cell migration there is provided a method of treating hyperplasia.
  • methods of treating breast cancer which may be HER2 positive or HER2 negative, including, for example, advanced breast cancer, stage IV breast cancer, locally advanced breast cancer, and metastatic breast cancer.
  • the cancer is lung cancer, including, for example, non-small cell lung cancer (NSCLC, such as advanced NSCLC), small cell lung cancer (SCLC, such as advanced SCLC), and advanced solid tumor malignancy in the lung.
  • NSCLC non-small cell lung cancer
  • SCLC small cell lung cancer
  • advanced solid tumor malignancy in the lung is ovarian cancer, head and neck cancer, gastric malignancies, melanoma (including metastatic melanoma), colorectal cancer, pancreatic cancer, and solid tumors (such as advanced solid tumors).
  • the cancer is any of (and in some embodiments selected from the group consisting of) breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, pancreatic cancer, soft-tissue sarcoma, Kaposi's sarcoma, carcinoid carcinoma, head and neck cancer, melanoma, ovarian cancer, mesothelioma, gliomas, glioblastomas, neuroblastomas, and multiple myeloma.
  • the cancer is a solid tumor.
  • the cancer is any of (in some embodiments, selected from the group consisting of) prostate cancer, colon cancer, breast cancer, head and neck cancer, pancreatic cancer, lung cancer, and ovarian cancer.
  • Individuals suitable for receiving these compositions depend on the nature of the therapeutic agent, as well as the disease/condition/disorder to be treated and/or prevented. Accordingly, the terms "individual” and “subject” include any of vertebrates, mammals, and humans depending on intended suitable use. In some embodiments, the individual is a mammal. In some embodiments, the individual is any one or more of human, bovine, equine, feline, canine, rodent, or primate. In some embodiments, the individual is a human.
  • the invention provides a method of treating carcinoma (such as colon carcinoma) in an individual, wherein the method comprises administering to the individual a composition comprising an effective amount of phospholipid-coated therapeutic agent nanoparticle.
  • carcinoma such as colon carcinoma
  • the compositions described herein can be administered alone or in combination with other pharmaceutical agents, including poorly water soluble pharmaceutical agents.
  • the composition comprises a taxane (such as paclitaxel)
  • a taxane such as paclitaxel
  • it can be co-administered with one or more other chemotherapeutic agents including, but are not limited to, carboplatin, Navelbine (vinorelbine), anthracycline (Doxil), lapatinib (GW57016), Herceptin, gemcitabine (Gemzar), capecitabine (Xeloda), alimta, cisplatin, 5-fluorouracil, epirubicin, cyclophosphamide, avastin, Velcade.
  • chemotherapeutic agents including, but are not limited to, carboplatin, Navelbine (vinorelbine), anthracycline (Doxil), lapatinib (GW57016), Herceptin, gemcitabine (Gemzar), capecitabine (Xeloda), alimta, cisplatin,
  • the taxane composition is co-administered with a chemotherapeutic agent selected from the group consisting of antimetabolites (including nucleoside analogs), platinum-based agents, alkylating agents, tyrosine kinase inhibitors, anthracycline antibiotics, vinca alkloids, proteasome inhibitors, macrolides, and topoisomerase inhibitors.
  • chemotherapeutic agent selected from the group consisting of antimetabolites (including nucleoside analogs), platinum-based agents, alkylating agents, tyrosine kinase inhibitors, anthracycline antibiotics, vinca alkloids, proteasome inhibitors, macrolides, and topoisomerase inhibitors.
  • chemotherapeutic agent selected from the group consisting of antimetabolites (including nucleoside analogs), platinum-based agents, alkylating agents, tyrosine kinase inhibitors, anthracycline antibiotics, vinca alkloids, prote
  • the dose is sufficient to effect a desirable response, such as a therapeutic or prophylactic response against a particular disease or condition.
  • the dosage of representative therapeutic agents (e.g., paclitaxel) administered can be about 1 to about 300 mg/m2, including for example about 10 to about 300 mg/m 2 , about 30 to about 200 mg/m 2 , and about 70 to about 150 mg/m 2 .
  • the dosage of a therapeutic agent (e.g., paclitaxel) in the composition can be in the range of about 50 to about 200 mg/m 2 when given on a 3 week schedule, or about 10 to about 100 mg/m 2 when given on a weekly schedule.
  • the dosage may be in the range of about 1-50 mg/m 2 .
  • Dosing frequency for the compositions of the invention includes, but is not limited to, at least about any of once every three weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or daily.
  • the interval between each administration is less than about a week, such as less than about any of 6, 5, 4, 3, 2, or 1 day. In some embodiments, the interval between each administration is constant.
  • the administration can be carried out daily, every two days, every three days, every four days, every five days, or weekly. In some embodiments, the administration can be carried out twice daily, three times daily, or more frequent.
  • the administration of the compositions of the invention can be extended over an extended period of time, such as from about a month up to about three years.
  • the dosing can be extended over a period of any of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, and 36 months.
  • the interval between each administration is no more than about a week.
  • compositions described herein can be administered to an individual via various routes, including, for example, intravenous, intra-arterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosal, and transdermal.
  • the compositions are administered by any acceptable route including, but not limited to, orally, intramuscularly, transdermal ⁇ , and intravenously.
  • the continuous phase preferably comprises an aqueous solution of tonicity modifiers, buffered to a pH range of about 5 to about 8.5. The pH may also be below 7 or below 6.
  • the pH of the composition is no less than about 6, including for example no less than about any of 6.5, 7, or 8 (such as about 7.5 or 8).
  • the nanoparticles of this invention can be enclosed in a hard or soft capsule, can be compressed into tablets, or can be incorporated with beverages or food or otherwise incorporated into the diet.
  • Capsules can be formulated by mixing the nanoparticles with an inert pharmaceutical diluent and inserting the mixture into a hard gelatin capsule of the appropriate size. If soft capsules are desired, a slurry of the nanoparticles with an acceptable vegetable oil, light petroleum or other inert oil can be encapsulated by machine into a gelatin capsule.
  • the invention provides methods of reducing side effects associated with administration of a therapeutic agent to a human, comprising administering to a human a pharmaceutical composition comprising the phospholipid coated therapeutic agent nanoparticle.
  • the invention provides methods of reducing various side effects associated with administration of the therapeutic agent, including, but not limited to, myelosuppression, neurotoxicity, hypersensitivity, inflammation, venous irritation, phlebitis, pain, skin irritation, peripheral neuropathy, neutropenic fever, anaphylactic reaction, hematologic toxicity, and cerebral or neurologic toxicity, and combinations thereof.
  • the invention provides methods for making the phospholipid- coated therapeutic agent nanoparticles.
  • the methods for the formation of nanoparticles of the invention include preparation under conditions of high shear forces (e.g., sonication, high pressure homogenization, or the like). Representative methods for forming nanoparticles under high shear force conditions are described in U.S. Patent Nos.
  • the therapeutic agent is dissolved in an organic solvent to provide a solution that is combined with an aqueous phospholipid solution to provide a mixture.
  • the mixture is subjected to high pressure homogenization.
  • Post- homogenization to the desired level the organic solvent is removed by evaporation to provide an aqueous dispersion.
  • the dispersion obtained can be further lyophilized to provide a particulate solid.
  • Suitable organic solvents include solvents in which the therapeutic agent is soluble, that are miscible with aqueous solution, and that can be removed by evaporation at reasonable temperature and pressure.
  • Representative useful solvents include ketones, esters, ethers, chlorinated solvents, and other solvents known in the art.
  • the organic solvent can be methylene chloride or chloroform/ethanol (for example, with a ratio of 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, or 9:1).
  • Pharmaceutically acceptable excipients can also be added to the composition. Suitable pharmaceutically acceptable excipients include solutions, emulsions, or suspensions. Other emulsion or nanoparticle formulations may also be prepared. An emulsion is formed by homogenization under high pressure and high shear forces.
  • Such homogenization is conveniently carried out in a high- pressure homogenizer, typically operated at pressures in the range of about 3,000 up to 30,000 psi. Preferably, such processes are carried out at pressures in the range of about 6,000 up to 25,000 psi.
  • the resulting emulsion comprises very small nanodroplets of the non-aqueous solvent containing the dissolved therapeutic agent and very small nanodroplets of the phospholipid.
  • Acceptable methods of homogenization include processes imparting high shear and cavitation such as, for example, high- pressure homogenization, high shear mixers, sonication, high shear impellers and the like.
  • Colloidal systems prepared in accordance with the present invention can be further converted into powder form by removal of the water (e.g., lyophilization) at a suitable temperature-time profile.
  • the lyophilized product e.g., particulate powder
  • the lyophilized product is readily reconstituted by addition of water, saline or buffer, without the need to use conventional cryoprotectants such as mannitol, sucrose, glycine and the like. While not required, it is of course understood that conventional cryoprotectants can be added to the pharmaceutical compositions if so desired.
  • the nanoparticles are prepared by microfluidization-solvent evaporation. In another embodiment, the nanoparticles are prepared by thin- film hydration.
  • phospholipids and paclitaxel were dissolved in ethanol and subjected to rotary evaporation until a thin film was formed and all the solvents were evaporated. The film was then hydrated using deionized (Dl) water to produce paclitaxel-loaded phospholipid nanoparticles.
  • the methods of the invention include methods of making pharmaceutical compositions comprising combining any of the compositions described herein with a pharmaceutically acceptable excipient.
  • the invention provides use of the compositions described herein in the manufacture of a medicament. Particularly, the manufacture of a medicament for use in the treatment of conditions described herein.
  • the pharmaceutical composition thereof described herein are also intended for use in the manufacture of a medicament for use in treatment of the conditions and, in accordance with the methods, described herein.
  • Synthetic High Density Lipoprotein (HDL) Complexes of Therapeutic Agents provides synthetic high density lipoprotein (HDL) complexes of therapeutic agents, compositions that include complexes, methods for preparing the complexes and compositions, and methods for the use of the complexes and compositions.
  • the present invention provides synthetic high density lipoprotein (HDL) complexes of therapeutic agents that are effective nanoparticle delivery vehicles for therapeutic agents (e.g., poorly water-soluble therapeutic agents).
  • Plasma lipoproteins are composed of lipid and protein components that form a globular complex designed to transport water-insoluble lipids in a physiological environment.
  • the two phase structure of lipoproteins includes an outer shell made up of amphiphilic components (phospholipid and protein components) and an interior core containing highly hydrophobic lipids. This two phase structure allows lipoproteins to fulfill their roles as drug delivery agents, particularly in the transport of water-insoluble drugs.
  • the present invention provides delivery vehicles are provided in a formulation of a therapeutic agent that is encapsulated in a synthetic self-assembled nanoparticle that includes a lipid binding protein and a lipid monolayer.
  • the interior of the particle represents a hydrophobic core region where therapeutic agents (e.g., poorly water-soluble therapeutic agents) may be incorporated.
  • the nanoparticle vehicle of the invention is composed of a shell (e.g., monolayer) surrounding a hydrophobic interior (i.e., core).
  • a shell e.g., monolayer
  • a hydrophobic interior i.e., core
  • the hydrophobic nature of the interior of the synthetic HDL particle of the invention allows the encapsulation of hydrophobic molecules, in a manner similar to the native core component of HDL (cholesteryl esters).
  • the character of those compounds that are appropriate candidates for encapsulation, including chemotherapeutic agents, can be defined by their octanol/water partition coefficient X log P (Wang et al. Chem. Inf Comput. Sci. 1997, 37, 615-621).
  • the coefficient for paclitaxel is 3.0.
  • therapeutic agents with X log P greater than 2.0 are excellent candidates for incorporation into the vehicle of the invention. This characteristic includes over half of the approved pharmaceutical agents currently employed for parenteral administration.
  • the term "poorly water-soluble therapeutic agent” refers to a therapeutic agent having an octanol/water partition coefficient X log P greater than 4.0.
  • the invention provides a synthetic self-assembled nanoparticle that includes a lipid layer (e.g., monolayer) comprising an amphiphilic lipid (e.g., a phosphatidylcholine) and one or more therapeutic agents.
  • self-assembly refers to the formation of synthetic HDL nanoparticles from ingredients (such as lipids and relatively low molecular weight proteins, such as apolipoprotein (e.g., apolipoprotein Al, also referred to herein as Apo-Al or ApoA-l) assembled into a particle of greater molecular weight without the application of a physical force, such as sonication, high pressure, membrane intrusion, or centrifugation.
  • the core (i.e., interior) of the particle is a hydrophobic region where the transported materials reside in a manner similar to the native cholesteryl esters in HDL.
  • Particles of the invention do not include a hydrophilic or aqueous core.
  • the shell (e.g., lipid monolayer) of the particle includes lipids (e.g., phospholipids) with their polar head groups facing away from the interior of the particle. Any suitable lipid may be used that along with a lipid binding protein to provide the scaffolding for the substantially spherical particle to accommodate the drug to be transported in the interior of the particle.
  • the term "monolayer-forming lipid” refers to a compound that is capable of forming a lipid monolayer serving as an outer shell of the basic lipoprotein structure.
  • the lipid shell is composed of phospholipids, such as phosphatidylcholines.
  • lipid binding protein refers to synthetic or naturally occurring peptides or proteins that are able to sustain a stable complex with lipid surfaces and thus able to function to stabilize the lipid shell the nanoparticle of the invention.
  • the nanoparticles of the invention may include one or more types of lipid binding proteins or apolipoproteins that are natural components of plasma lipoproteins.
  • nanoparticles can be prepared using small synthetic peptides that may serve as surrogates for native lipoproteins.
  • Apolipoproteins generally include a high content of amphipathic alpha-helix motif that facilitates their ability to bind to hydrophobic surfaces, including lipids.
  • apolipoproteins An important characteristic of apolipoproteins is to support the structure of monolayers, vesicles or bilayers, composed primarily of phospholipids and to transform them into disc-shaped complexes. Under physiological conditions, the discoidal complexes undergo a transition to a spherical structure.
  • the present invention provides nanoparticle delivery vehicles, methods for using the nanoparticle delivery vehicles, and methods for making the nanoparticle delivery vehicles.
  • Nanoparticle Delivery Vehicles In one aspect, the invention provides high density lipoprotein (HDL) nanoparticle delivery vehicles. On administration, the nanoparticle delivery vehicles of the invention are stable in the circulatory system.
  • HDL high density lipoprotein
  • the nanoparticle delivery vehicles of the invention are stable in the circulatory system.
  • the term “stable in the circulatory system” refers to the ability of the vehicle to substantially maintain its therapeutic agent content while in the circulatory system.
  • the vehicle maintains greater than 80 percent, greater than 85 percent, greater than 90 percent, greater than 95 percent, or greater than 99 percent of the therapeutic agent loaded into the nanoparticle delivery vehicle.
  • the nanoparticle delivery vehicles substantially maintain their therapeutic agent content by increasing the hydrophobicity of the portion of the vehicle responsible for therapeutic agent transport.
  • the increase in the vehicle hydrophobicity is effective to increase stability of poorly water-soluble therapeutic agents (e.g., therapeutic agents having an octanol/water partition coefficient X log P greater than 4.0) in the vehicle.
  • the core (e.g., interior) of the nanoparticle has increased hydrophobicity compared to native HDL particles.
  • the hydrophobicity of one or more lipid components of the vehicle's core is increased relative to the hydrophobicity of the component in native HDL.
  • the shell (e.g., lipid monolayer) of the nanoparticle has increased hydrophobicity compared to native HDL particles.
  • the hydrophobicity of one or more phospholipids of the vehicle's shell is increased relative to the hydrophobicity of the component in native HDL.
  • the hydrophobicity of the core and the shell of the vehicle are increased compared to native HDL.
  • the core and/or shell of the vehicle can further include components not found in native HDL particles that are effective to increase the hydrophobicity of the vehicle's core and/or shell.
  • the hydrophobicity of the vehicle can be increased by a variety of methods including increasing the hydrophobicity of HDL components by, for example, increasing the number of carbon atoms in the fatty acid chains of the component phospholipids or cholesteryl esters.
  • the vehicles of the invention substantially maintain their therapeutic agent content in the circulatory system (at concentrations below the solubility limit of the therapeutic agent, the therapeutic agent remains in the vehicle).
  • the invention provides a nanoparticle delivery vehicle, comprising a high density lipoprotein complex.
  • the complex comprises: (a) a hydrophobic core having increased hydrophobicity compared to native high density lipoprotein, the core comprising (i) a lipid component, and (ii) a therapeutic agent (e.g., a poorly water-soluble therapeutic agent), and (b) a shell (e.g., a hydrophilic shell) surrounding the core, the shell comprising a phospholipid.
  • the vehicle's core is a substantially non-aqueous environment. On administration, the vehicle's shell is in contact with the aqueous environment of the circulatory system.
  • the lipid component includes a lipid binding protein. Representative lipid binding proteins include apolipoprotein Al (ApoA-1). In certain embodiments, the lipid component includes cholesterol.
  • the lipid component includes one or more cholesteryl esters as described above, including cholesterol fatty acid esters.
  • Representative cholesterol fatty acid esters include cholesteryl laurate, cholesteryl myristate, cholesteryl palmitate, cholesteryl stearate, and cholesteryl oleate.
  • the lipid component includes one or more of a sphingomyelin, a cationic phospholipid, and a glycolipid.
  • the lipid component includes a phosphatidylcholine.
  • phosphatidylcholines include dimyristoylphosphatidylcholine (DMPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), egg yolk phosphatidylcholine (egg PC), soybean phosphatidylcholine, and mixtures thereof.
  • the lipid component includes a mixture of a phosphatidylcholine, cholesterol, and a cholesterol fatty acid ester.
  • the vehicle of the invention includes a therapeutic agent (e.g., a poorly water-soluble therapeutic agent).
  • the nature of the therapeutic agent effectively delivered by the vehicle of the invention is not particularly critical so long as the therapeutic agent is advantageously retained in the vehicle while the vehicle is in the circulatory system (e.g., poorly water soluble therapeutic agent).
  • Effectively delivered therapeutic agents include anti-inflammatory agents (i.e., therapeutic agents effective for treating inflammation and inflammatory diseases), therapeutic agents effective for treating atherosclerosis, and chemotherapeutic agents.
  • a representative chemotherapeutic agent is paclitaxel.
  • the vehicle e.g., vehicle shell
  • Suitable phospholipids include those described above with regard to the nanoparticles of the invention.
  • one or more of the shell's phospholipid has increased hydrophobicity compared to phospholipids in native high density lipoprotein.
  • Suitable phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, and phosphatidic acids.
  • the phospholipid is a diacylphosphatidylcholine.
  • diacylphosphatidylcholines include distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dilinoleoylphosphatidylcholine DLPC), palmitoyloleoylphosphatidylcholine (POPC), palmitoyllinoleoylphosphatidylcholine, stearoyllinoleoylphosphatidylcholine stearoyloleoylphosphatidylcholine, stearoylarachidoylphosphatidylcholine, didecanoylphosphatidylcholine (DDPC), dierucoylphosphatidylcholine (DEPC), dilinoleoylphosphatidylcholine (DLOPC), dimyristoylphosphatidylcholine (DMPC), myristoylpalmitoyl
  • Representative therapeutic agents advantageously delivered by the synthetic high density lipoprotein (HDL) complex of the invention include the representative therapeutic agent described above for the nanoparticle of the invention, including antineoplastic agents (e.g., paclitaxel) and immunosuppressive agents.
  • the vehicle has substantially the same electrophoretic mobility, size, and chemical composition as a native high density lipoprotein.
  • the vehicle has a size from about 5 to about 100 nm.
  • the vehicle has a molecular weight of about 120k to about 500k Dalton.
  • the vehicle is spherical, oval, or discoidal in shape.
  • the invention provides pharmaceutical compositions that include a nanoparticle delivery vehicle and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier is selected based on the mode of vehicle administration. Suitable carriers for intravenous administration include saline and dextrose solutions known in the art.
  • methods for using the nanoparticle delivery vehicle are provided.
  • the invention provides a method for delivering a therapeutic agent (e.g., a poorly water-soluble therapeutic agent) to a subject.
  • a nanoparticle delivery vehicle of the invention is administered to a subject.
  • the invention provides a method for the treatment of cancer.
  • a therapeutically effective of a nanoparticle delivery vehicle of the invention is administered to a subject in need thereof.
  • the cancer is one treatable by administration of the specific therapeutic agent (e.g., a poorly water-soluble therapeutic agent).
  • the cancer is prostate cancer, ovarian cancer, or breast cancer.
  • the therapeutic agent is a chemotherapeutic agent.
  • the therapeutic agent is paclitaxel.
  • the invention provides methods for the treatment of inflammatory diseases and methods for treatment of atherosclerosis. In these methods, a therapeutically effective of a nanoparticle delivery vehicle of the invention is administered to a subject in need thereof.
  • the therapeutic agent is an anti-inflammatory agent or an agent effective for treating atherosclerosis, respectively.
  • an effective amount of the vehicle is delivered systemically to a subject in need thereof.
  • the vehicle is suitably administered parenterally, intravenously, intramuscularly, subcutaneously, transmucosally, or transdermally.
  • the term "subject" refers to any cell, animal tissue, or a vertebrate animal.
  • the individual is a vertebrate, such as a human, a nonhuman primate, or an experimental animal, such as a mouse or rat.
  • particles are formulated as a carrier, suitable for administration to a subject.
  • effective amount refers to the amount of a therapeutic agent sufficient to bring about the desired results in an experimental setting.
  • a “therapeutically effective amount” or “therapeutic dose” refers to an amount of a therapeutic agent that is sufficient to produce beneficial clinical results, such as reduction in tumor size or remission for cancer patients.
  • the invention provides a method for making the nanoparticle delivery vehicle.
  • the method comprises: (a) mixing lipid components in a suitable organic solvent to give a lipid mixture; (b) adding a therapeutic agent (e.g., a poorly water-soluble therapeutic agent to the lipid mixture to provide a lipid-therapeutic agent mixture; (c) drying the lipid-therapeutic agent mixture under nitrogen to provide a solid; (d) dispersing the solid in an aqueous solution to provide a dispersed mixture; (e) mixing the dispersed mixture in a buffer to provide a buffered mixture; (f) adding a suitable salt to the buffered mixture to provide a salt mixture; (g) adding a lipid binding protein to the salt mixture to provide a lipid binding protein mixture; (h) incubating the lipid binding protein mixture to provide an incubated mixture; and (i) subjecting the incubated mixture to dialysis with one or more buffer changes to facilitate the self-assembly and formation of
  • a therapeutic agent e
  • the lipid components include a phosphatidylcholine, cholesterol, and a cholesterol ester.
  • the organic solvent is dimethylsulfoxide.
  • the therapeutic agent is a chemotherapeutic agent.
  • the therapeutic agent is paclitaxel.
  • the aqueous solution is 3% dimethylsulfoxide.
  • the salt is sodium cholate.
  • the lipid binding protein is apolipoprotein Al. The preparation of a representative nanoparticle delivery vehicle of the invention that includes paclitaxel is described in Example 1. The following examples are provided for the purpose of illustrating, not limiting, the invention.
  • Recombinant ApoA-l is prepared as described in Ryan et al. (2003) Protein Expression and Purification 27:98-103, and can be used to prepare representative HDL/paclitaxel complexes of the invention.
  • the particles are prepared by a process involving cholate dialysis as described below to produce a spherical structure with paclitaxel in the interior hydrophobic core region.
  • the lipid mixture (egg yolk phosphatidylcholine [PC], cholesterol and cholesteryl oleate in the ratio of 3.8:1:88.5) and 2 mg paclitaxel is dried under nitrogen to provide a thin film, which is then dispersed in dimethyl sulfoxide and subsequently in 1.4 ml of 10 mM Tris, 0.1 M KCI, 1 mM EDTA, pH 8.0).
  • Sodium cholate, 140 ⁇ (100 mg/ml stock in [0.15 M NaCI 0.003 M KCI, 0.15 M KH2P04, pH 7.4, designated as PBS]) is added to produce mixtures with a final PC to cholate molar ratio of about 1:1.6.
  • ApoA-l (12.7 mg/ml) in 0.4 ml of PBS is added to this mixture and the final volume is adjusted to 2 ml with PBS.
  • the lipid/protein/cholate mixture is then incubated for 12 hrs at 4 °C, followed by dialysis (2 liter of PBS, for two days) with three buffer changes.
  • Successful paclitaxel nanoparticles formulations include Abraxane and Genexol-PM.
  • Abraxane contains human derived albumin and Genexol-PM utilizes a synthetic polymer to solubilize water insoluble paclitaxel.
  • This example describes the use of biocompatible and injectable phospholipid and cholesteryl ester, a stabilizing component of high density lipoprotein nanoparticles, combinations to produce a stable nanoparticle formulation of paclitaxel for breast cancer treatment.
  • the effect of lipid composition and methods of preparation on drug loading and physical stability of the nanoparticle formulations were evaluated.
  • the formulation parameters included type of phospholipids, fatty acid chain lengths in cholesteryl ester, combination of phospholipid and cholesteryl esters, and drug-lipid ratio.
  • the process parameters such as temperature of water for hydration, buffer components, pH of buffer were studied and their impact on drug loading, particle size and physical stability were evaluated.
  • the short-term stability evaluation of nanoparticles prepared with different cholesteryl esters demonstrated that addition of 1-10% of cholesteryl esters produced nanoparticle with a loading of more than 90% paclitaxel and with particle size of less than 275nm.
  • the formulation is found to be stable for 24h at 4°C.
  • the stability of the formulation was also evaluated at different temperatures before and after lyophilization with the addition of different buffers of different pH.
  • Paclitaxel (PTX) nanoformulations were prepared using a combination of phospholipids and cholesteryl esters with different chain lengths.
  • the paclitaxel nanoformulations were prepared by two different methods, microfluidization-solvent evaporation and thin film hydration.
  • Microfluidization-solvent evaporation entailed forming the PTX-phospholipid cholesteryl ester nanoparticles by a LV1 low volume Microfluidizer ® processor microfluidization.
  • the organic solvents containing paclitaxel and phospholipids cholesteryl esters were added to an aqueous phase and the emulsion was run through the microfluidizer to obtain nanoemulsion.
  • the solvents from the nanoemulsion were removed by rotoevaporation to obtain nanosuspension of paclitaxel.
  • the preparation of paclitaxel nanoparticles by thin-film hydration entailed preparing the phospholipid cholesteryl ester film by dissolving paclitaxel and phospholipids and cholesteryl ester in organic solvent.
  • the dry film was hydrated with water for visual, microscopic, size and loading efficiency measurements of the resulting unfiltered and filtered formulations.
  • a comparison of the particle size, loading efficiency, polydispersity, diameter and zeta potential of the different combination of the phospholipid and cholesteryl ester as well as the human serum albumin nanoformulations is shown in Table 2.
  • the particle size and size distribution measurements were carried out using Zetasizer Nano-ZS and the Zav hydrodynamic diameter of the samples was determined by cumulative analysis.
  • the particle size and particle size distribution by intensity were measured by photon correlation spectroscopy (PCS) using dynamic laser light scattering (4 mW He-Ne laser with a fixed wavelength of 633 nm, 173° backscatter at 25°C) in 10 mm diameter cells.
  • ELISA was used to measure paclitaxel concentration in lipid nanoparticles.
  • the thin-film hydration method produced particles of higher paclitaxel loading than microfluidization-solvent evaporation method.
  • PLs or lyso-PLs alone did not produce smaller particles of size ⁇ 200 nm in either methods. Both the methods produced particles of size smaller than 200nm.
  • Figure 4 is the particle size distribution graph by dynamic laser light scattering for the optimized formulation of PTX-NP formulation stabilized with combination of PC and cholesteryl oleate.
  • the formulation was filterable through 0.2 ⁇ filter and the filtered NP formulation of PTX has monomodal size distribution with a polydispersity index of 0.2.
  • the Zav of the optimized formulation was ⁇ 250 nm.
  • a typical vial image for LM-102 20 nanoformulation is shown in Figure 5.
  • paclitaxel used in the preparation of phospholipid cholesteryl oleate 20 (LM-102) can affect PTX -NPs drug loading and nanoparticle size.
  • the effects of paclitaxel amount on particle size and entrapment efficiency for LM-102 by method 2 are presented in Figures 7A and B. There was significant increase in the entrapment of PTX in LM- 102 for lower amount of paclitaxel (2.5 mg-5.0 mg)
  • LM-102 Stability of LM-102 at refrigerated temperature (4°C) and T are shown in Figure 8.
  • the formulations were prepared by method 2 with paclitaxel amount of 2.5 mg to 10 mg.
  • LM-102 was found to be stable for 24h at 4°C for the drug loadings of 2.5 mg and 20 5 mg.
  • Paclitaxel-loaded LM-102 formulations were frozen at -20C for ⁇ 24h with and without sucrose.
  • the size of the thawed formulations is shown in Figure 9. The formulation is stable for one freeze-thaw cycle with sucrose as additive.
  • sucrose in combination with PBS and histidine buffer were examined.
  • Sucrose in amounts of 10-20% were found to be best in stabilizing the 5 particles on lyophilization as shown in Fig. 10.
  • the formulations were also stable for 24h at RT and 4C after reconstitution (Fig. 10).
  • the combination of PC-10 and cholesteryl oleate produced smallest size PTX-NP by the thin film hydration method.
  • the highest entrapment efficiency of greater than 80% was achieved for the formulation LM-102.
  • Water of temp. 40°C for rehydration step produced best loading for LM-102 by thin-film hydration method.
  • the optimized formulation of LM-102 is stable for 24h at 4 Q C.
  • Sucrose is the best lyoprotectant for stabilization of the formulation on lyophilization.
  • the optimized formulation is stable for 24hrs at RT and 4°C after reconstitution Example 3
  • paclitaxel nanoparticles formulations include Abraxane ® (an albumin bound nanoparticle paclitaxel) and Genexol-PM ® (a polymer bound nanoparticle paclitaxel).
  • Genexol-PM ® has been developed as a 2nd generation Abraxane ® .
  • the development of Genexol-PM ® was a significant step forward in manufacturing with utilization of a one pot synthesis technique using a biodegradable di- block copolymer composed of methoxy-poly (ethylene glycol)-poly(lactide) to form nanoparticles with paclitaxel containing hydrophobic core and a hydrophilic shell.
  • clinical hypersensitivity and instability in serum/plasma remain problematic.
  • Nanoparticle synthesis was conducted using microfluidization-solvent evaporation (similar to Abraxane method) and thin-film hydration (one pot method similar to Genexol-PM method). Briefly, in thin film hydration, phospholipids and paclitaxel were dissolved in ethanol and then subjected to rotary evaporation until a thin film was formed and all the solvents were evaporated.
  • the film was then hydrated using deionized (Dl) water to produce paclitaxel loaded phospholipid nanoparticles.
  • Nanoparticle size and zeta potential were measured using a Malvern ZS DLS system.
  • the formulation was subjected to serial filtration using 1.2 ⁇ , ⁇ . ⁇ , 0.45 ⁇ and 0.2 ⁇ syringe filters.
  • the drug incorporation/loading in phospholipid nanoparticles was measured using ELISA.
  • Electrochemical properties of the formulation were measured using screen printed carbon nanotube electrodes from DropSens and a PGSTAT204 Autolab station from Metrohm.
  • NPB nanoparticle phospholipid bound paclitaxel formulations
  • Cyclic voltammetry (CV) scans of various model phospholipid nanoparticles were performed: LDL (Low Density Lipoprotein) and HDL (High Density Lipoprotein) for monolayer phospholipid nanoparticles and ghost RBC (Red Blood Cells) for bilayer phospholipid nanoparticles. All model lipid particles behaved as microfluidization-solvent evaporation with nanoparticles exhibiting the typical square profile of high capacitance material. The data demonstrated that the CV of thin film hydration was not due to the phospholipid encapsulating the paclitaxel but due to the amount of paclitaxel in the nanoparticle.
  • Capacitance of a carbon-based electrode consists of two major components: the electrical double layer capacitance due to the electrostatic attraction of charged carbon surfaces to electrolyte ions and the pseudocapacitance due to the Faradic reactions of electroactive species on the carbon surfaces. During electrochemical evaluations, the NPBs were treated as ionic liquid capacitance material.
  • Low capacitance is suggestive of weakened charge accumulation in the electrode - electrolyte interface which depends on the mesoporosity and electrolyte accessibility of the capacitance. As such it is indicative that the low negative charge paclitaxel nanoparticles developed by thin film hydration method have less electrolyte accessibility than those produced by the microfluidization-solvent evaporation method.
  • Paclitaxel (PTX) nanoformulations were prepared using a combination of phospholipids and/or cholesteryl ester or albumin. Nanoformulations not containing paclitaxel were also produced. The paclitaxel nanoformulations were prepared by two different methods, microfluidization-solvent evaporation and thin film hydration. Microfluidization-solvent evaporation entailed forming the PTX- phospholipid cholesteryl ester nanoparticles by a LV1 low volume Microfluidizer ® processor microfluidization.
  • the organic solvents containing paclitaxel and phospholipids cholesteryl esters were added to an aqueous phase and the emulsion was run through the microfluidizer to obtain nanoemulsion.
  • the solvents from the nanoemulsion were removed by rotoevaporation to obtain nanosuspension of paclitaxel.
  • the preparation of paclitaxel nanoparticles by thin-film hydration entailed preparing the phospholipid cholesteryl ester film by dissolving paclitaxel and phospholipids and cholesteryl ester in organic solvent.
  • the dry film was hydrated with water for visual, microscopic, size and loading efficiency measurements of the resulting unfiltered and filtered formulations.
  • a comparison of the particle size, loading efficiency, polydispersity, diameter and zeta potential of the different combination of the phospholipid and cholesteryl ester as well as the human serum albumin nanoformulations is shown in Table 3.
  • Figure 13A-D shows plots of the size and size distribution of 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI3, lOmg paclitaxel nanoparticle made by microfluidization-solvent evaporation; 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 , 2.5mg paclitaxel nanoparticle made by thin film evaporation; 50mg PC10, 0.5mg cholesteryl oleate, 15% EtOH in HCCI 3 , 2.5mg paclitaxel nanoparticle made by thin film evaporation and 40mg paclitaxel, 15% EtOH in HCCI 3 , 30mg/mL albumin nanoparticle made by microfluidization-solvent evaporation.
  • Figure 14A-D shows the cyclic voltammetry scans of40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 , lOmg paclitaxel nanoparticle made by microfluidization-solvent evaporation; 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 , 2.5mg paclitaxel nanoparticle made by thin film evaporation; 50mg PC10, 0.5mg cholesteryl oleate, 15% EtOH in HCCI 3 , 2.5mg paclitaxel nanoparticle made by thin film evaporation and 40mg paclitaxel, 15% EtOH in HCCI 3 , 30mg/mL albumin nanoparticle made by microfluidization-solvent evaporation.
  • Figure 15A-E shows cyclic voltammetry plots of 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 without drug nanoparticle made by microfluidization-solvent evaporation; 40mg PC10, lOmg LysoPCIO, 15% EtOH in HCCI 3 , without drug nanoparticle made by thin film evaporation; human serum albumin; Grifols stabilized human serum albumin and 40mg paclitaxel, 15% EtOH in HCCI 3 , Grifols stabilized human serum albumin.
  • Nanoparticle synthesis was conducted using a two-step method whereby the drug is first emulsified in presence of solvent and then nanofabricated in presence of polymer. Nanoparticle size and zeta potential were measured using a Malvern ZS DLS system. The formulation was subjected to serial filtration using 1.2 ⁇ , ⁇ . ⁇ , 0.45 ⁇ and 0.2 ⁇ syringe filters. The drug incorporation/loading was measured using ELISA. Electrochemical properties of the formulation were measured using screen printed carbon nanotube (CNT) electrodes from DropSens and a PGSTAT204 Autolab Potentiostat from Metrohm.
  • CNT screen printed carbon nanotube
  • the drug being evaluated in this study is paclitaxel- a water insoluble drug that can only be solubilized in Cremophor EL for intravenous administration. Only nanomedicinization allowed paclitaxel to be formulated without solvent. Cyclic voltammograms were generated from -0.4V to either 0.7V (phospholipids) or 1.2V (albumin). Scan rates of 0.005, 0.01, 0.025, 0.05, 0.1, and 0.2 V/s were examined.
  • a series of stable nanomedicinized paclitaxel was created using chloroform or ethanol as solvent and phospholipid or albumin as polymer. Each formulation exhibited a distinct cyclic voltammetry (CV) scan. The CV scan was highly dependent on the polymer used. Monolayer and bilayer phospholipids behaved similarly as polymer with or without paclitaxel. Microfluidization-solvent evaporation formulations are characterized by low drug loading, positive zeta potential and cyclic voltammograms indicative high capacitance materials. Utilizing the same materials, process thin film hydration formulations demonstrate greater drug loading, negative to neutral zeta potential and voltammograms of low capacitance material.
  • Albumin formulations of paclitaxel are characterized by milligram levels of drug loading, negative zeta potentials and cyclic voltammograms demonstrating an albumin peak in 0.005 V/s scans. The pattern is maintained in the absence of paclitaxel. The albumin peak is magnified in scans of albumin stabilized with sodium acetyltryptophan and sodium caprylate.
  • any indication that a feature is optional is intended provide adequate support (e.g., under 35 U.S.C. 112 or Art. 83 and 84 of EPC) for claims that include closed or exclusive or negative language with reference to the optional feature.
  • Exclusive language specifically excludes the particular recited feature from including any additional subject matter. For example, if it is indicated that A can be drug X, such language is intended to provide support for a claim that explicitly specifies that A consists of X alone, or that A does not include any other drugs besides X. "Negative" language explicitly excludes the optional feature itself from the scope of the claims.
  • Non-limiting examples of exclusive or negative terms include “only,” “solely,” “consisting of,” “consisting essentially of,” “alone,” “without”, “in the absence of (e.g., other items of the same type, structure and/or function)" "excluding,” “not including”, “not", “cannot,” or any combination and/or variation of such language.
  • a dog is intended to include support for one dog, no more than one dog, at least one dog, a plurality of dogs, etc.
  • qualifying terms that indicate singularity include “a single”, “one,” “alone”, “only one,” “not more than one”, etc.
  • qualifying terms that indicate (potential or actual) plurality include “at least one,” “one or more,” “more than one,” “two or more,” “a multiplicity,” “a plurality,” “any combination of,” “any permutation of,” “any one or more of,” etc.

Abstract

La présente invention concerne des nanoparticules d'agents thérapeutiques, des formulations de nanoparticules convenant à l'injection, des méthodes d'administration d'agents thérapeutiques et de traitement de maladies et d'états pouvant être traités par les agents thérapeutiques à l'aide desdites formulations, en particulier la formulation et la caractérisation de nanoparticules contenant des taxanes tels que le paclitaxel.
PCT/US2017/058034 2016-10-24 2017-10-24 Nanoformulations d'ester de cholestéryle-phospholipide et procédés associés WO2018081083A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662412132P 2016-10-24 2016-10-24
US62/412,132 2016-10-24
US201762511996P 2017-05-27 2017-05-27
US62/511,996 2017-05-27

Publications (1)

Publication Number Publication Date
WO2018081083A1 true WO2018081083A1 (fr) 2018-05-03

Family

ID=62023968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/058034 WO2018081083A1 (fr) 2016-10-24 2017-10-24 Nanoformulations d'ester de cholestéryle-phospholipide et procédés associés

Country Status (1)

Country Link
WO (1) WO2018081083A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022087452A1 (fr) * 2020-10-23 2022-04-28 Northwestern University Médicaments hydrophobes dans des nanoparticules de lipoprotéine haute densité (hdl) à noyau organique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088042A1 (fr) * 2013-12-11 2015-06-18 Okinawa Institute Of Science And Technology School Corporation Procédé pour une libération contrôlée à l'aide d'impulsions laser femtoseconde
WO2016115626A1 (fr) * 2015-01-19 2016-07-28 The Royal Institution For The Advancement Of Learning/Mcgill University Vésicules sensible à l'oxydoréduction
US20160346221A1 (en) * 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088042A1 (fr) * 2013-12-11 2015-06-18 Okinawa Institute Of Science And Technology School Corporation Procédé pour une libération contrôlée à l'aide d'impulsions laser femtoseconde
WO2016115626A1 (fr) * 2015-01-19 2016-07-28 The Royal Institution For The Advancement Of Learning/Mcgill University Vésicules sensible à l'oxydoréduction
US20160346221A1 (en) * 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FANJUL-BOLADO ET AL.: "Electrochemical study and flow injection analysis of paracetamol in pharmaceutical formulations based on screen-printed electrodes and carbon nanotubes", ANALYTICA CHIMICA ACTA, vol. 638, 21 February 2009 (2009-02-21), pages 133 - 138, XP026031852 *
GOWDA ET AL.: "Electrochemical behavior of paclitaxel and its determination at glassy carbon electrode", ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 9, no. 1, 10 December 2013 (2013-12-10), pages 42 - 49, XP055478937 *
MURTHA ET AL.: "Synthesis of the Cholesteryl Ester Prodrugs Cholesteryl Ibuprofen and Cholesteryl Flufenamate and Their Formulation into Phospholipid Microemulsions", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 83, no. 9, 30 September 1994 (1994-09-30), pages 1222 - 1228, XP000465804 *
SONG ET AL.: "Preparation and in vitro properties of redox-responsive polymeric nanoparticles for paclitaxel delivery", COLLOIDS AND SURFACES B: BIOINTERFACES, vol. 87, 15 June 2011 (2011-06-15), pages 454 - 463, XP028248634 *
TAKEOKA ET AL.: "Electrochemical control of drug release from redox-active micelles", JOURNAL OF CONTROLLED RELEASE, vol. 33, no. 1, 31 January 1995 (1995-01-31), pages 79 - 87, XP000482907 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022087452A1 (fr) * 2020-10-23 2022-04-28 Northwestern University Médicaments hydrophobes dans des nanoparticules de lipoprotéine haute densité (hdl) à noyau organique

Similar Documents

Publication Publication Date Title
Large et al. Liposome composition in drug delivery design, synthesis, characterization, and clinical application
US20180221289A1 (en) Phospholipid-cholesteryl ester nanoformulations and related methods
US11413244B2 (en) Liposome composition and pharmaceutical composition
JP2006508126A (ja) 薬学的製剤のタンパク質安定化されたリポソーム製剤
WO2007028341A1 (fr) Nanomicelles servant de medicaments anticancereux a polyethylene phospholipides glycolyles contenant des vinca alcaloides
US10772834B2 (en) Liposome composition and method for producing same
US11684575B2 (en) Liposome composition and method for producing same
CN111437259A (zh) 包含吉西他滨或其盐的脂质体组合物
US10646442B2 (en) Liposome composition and method for producing same
Layek et al. Recent advances in lipid-based nanodrug delivery systems in cancer therapy
US20180153818A1 (en) Phospholipid-coated therapeutic agent nanoparticles and related methods
Mehanna et al. Pharmaceutical particulate carriers: lipid-based carriers
WO2016196648A1 (fr) Nanoparticules d'agent thérapeutique revêtues de phospholipide et procédés associés
US20210128471A1 (en) Liposome composition and method for producing the same
US20180200195A1 (en) Stabilized high drug load nanocarriers, methods for their preparation and use thereof
WO2018081083A1 (fr) Nanoformulations d'ester de cholestéryle-phospholipide et procédés associés
WO2017218630A2 (fr) Nanoparticules d'agent thérapeutique revêtues de phospholipide et procédés associés
KR100996975B1 (ko) 혈류 내 순환시간 증가를 위한 단백질로 수식된 리포솜 및이의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17864105

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17864105

Country of ref document: EP

Kind code of ref document: A1